Dr Pierre Meulien

Guest Contributor
June 24, 2015

Dr Pierre Meulien has stepped down as president and CEO of Genome Canada to become executive director of the Innovative Medicines Initiative (IMI). Meulien departed Genome Canada July 17th and takes up his IMI duties in Brussels in mid-September to lead the second phase of the €3.3-billion drug research program between the European Union and European pharmaceutical industry. He replaces Dr Michael Goldman whose term ended last December. Meulien arrived at Genome Canada in 2010 and has overseen the organization's evolution from a funder of primarily basic research to one that supports applied research across many sectors. Prior to joining Genome Canada, he was chief scientific officer at Genome British Columbia, building on a series of executive positions that included chief executive of the Dublin Molecular Medicine Centre (now Molecular Medicine Ireland), director of research for Aventis Pasteur in Lyon, France and senior VP R&D in Toronto. Previously, Meulien worked for Strasbourg-based Transgene. He holds a PhD in molecular medicine from the Univ of Edinburgh and worked as a post-doctoral researcher at the Institute Pasteur….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.